Chemical Structure : JIN-A02
货号: PC-26083Not For Human Use, Lab Use Only.
JIN-A02 is a potent, mutant-selective, orally available fourth-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), overcomes C797S-mediated resistance.
| 规格 | 价格 | 库存 | 数量 |
|---|
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
JIN-A02 is a potent, mutant-selective, orally available fourth-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), overcomes C797S-mediated resistance.
JIN-A02 exhibits potent antiproliferative activity against a panel of Ba/F3 cell lines harboring clinically relevant EGFR mutations with IC90 of 117 nM (EGFR_E19del/C797S), 231 nM (EGFR_L858R/C797S), 192 nM (EGFR_E19del/T790M/C797S), and 359 nM (EGFR_L858R/T790M/C797S).
JIN-A02 demonstrates potent antiproliferative activity in preclinical NSCLC models harboring EGFR_C797S and T790M mutations, with superior inhibition of EGFR signaling compared to osimertinib.
JIN-A02 elicited substantial tumor regression, indicating robust in vivo efficacy in both subcutaneous and orthotopic intracranial xenograft NSCLC models.
| 分子量 | ||
| 分子式 | ||
| 外观性状 | Solid | |
| 储存条件 |
|
|
| Solubility |
10 mM in DMSO |
|
1. Lee EJ, et al. Clin Cancer Res. 2026 Feb 6. doi: 10.1158/1078-0432.CCR-25-3720.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright